Document 0780
 DOCN  M9610780
 TI    Hospital costs of treating haemophilic patients infected with HIV.
 DT    9601
 AU    Kennelly JM; Tolley KH; Ghani AC; Sabin CA; Maynard AK; Lee CA;
       Haemophilia Centre, Royal Free Hospital, London, UK.
 SO    AIDS. 1995 Jul;9(7):787-93. Unique Identifier : AIDSLINE MED/96035243
 AB    OBJECTIVE: To calculate the costs of treating HIV-infected haemophilic
       patients. DESIGN: Two-year retrospective study of hospital-based
       resource use and costs, from April 1991 to March 1993. SETTING:
       Haemophilia Centre and Haemostasis Unit, Royal Free Hospital and School
       of Medicine, London, UK. PATIENTS: Sixty patients infected with HIV
       between October 1979 and July 1985. RESULTS: During the 2-year period a
       total of 1668 hospital visits were made by patients. The mean number of
       episodes per patient-year (PY) was 0.6 inpatient admissions, 11.5
       outpatient visits and 1.8 day cases. The mean cost per PY was 32,528
       pounds, with the majority of this spent on clotting factor concentrate
       products and haemophilia inpatient admissions (81%). A mean cost for
       HIV-related treatment of 6050 pounds was estimated. The additional cost
       incurred in switching this group of haemophilic patients from
       intermediate-purity factor concentrate to high-purity products was 8614
       pounds per PY. When clotting factor concentrate and expenditure on
       haemophilia-related inpatient admissions were excluded, the mean cost of
       treating HIV infection per PY was 6065 pounds, varying with CD4+ count
       (< or = 50 x 10(6)/l, 13,093 pounds; 51-200 x 10(6)/l, 6521 pounds;
       201-500 x 10(6)/l, 2848 pounds; > 501 x 10(6)/l, 1497 pounds).
       CONCLUSIONS: CD4+ count may be used as a marker of costs of HIV
       infection. The HIV-related cost estimates can be used for the planning
       of current and future hospital-based care in the National Health Service
       in the United Kingdom. The switch from intermediate-purity factor
       concentrate to high-purity products has increased the mean HIV-related
       cost per PY of treating haemophilic patients infected with HIV.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS/DRUG THERAPY/
       *ECONOMICS  Adult  Aged  CD4 Lymphocyte Count
       Hemophilia/COMPLICATIONS/*ECONOMICS/THERAPY  *Hospital Costs  Human
       London  Male  Middle Age  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).